Published in Medical Letter on the CDC and FDA, September 5th, 2004
The FDA's decision was based on the findings of the ASCOT trial (Anglo-Scandinavian cardiac outcomes trial), which found that the lowest dose of Lipitor (10 mg) reduced the relative risk of heart attack by 36% compared to placebo. Because these significant benefits were seen so early, the trial was ended nearly 2 years ahead of schedule.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.